The Technical Analyst
Coeptis Therapeutics, [COEP]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Coeptis Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.60% $0.360
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.28 mill |
| EPS: | -0.610 |
| P/E: | -0.590 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 34.11 mill |
| Avg Daily Volume: | 0.270 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.590 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.590 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0192 (-94.66%) $-0.341 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.310 - 0.410 ( +/- 13.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-10 | Cogley Brian | Buy | 5 000 | Common Stock |
| 2024-01-10 | Cogley Brian | Sell | 0 | Common Stock |
| 2024-01-12 | Desilva Tara | Buy | 1 800 | Common Stock |
| 2024-01-12 | Desilva Tara | Buy | 466 | Common Stock |
| 2024-01-05 | Yerace Daniel Alexander | Buy | 10 850 | Common Stock |
| INSIDER POWER |
|---|
| 67.24 |
| Last 46 transactions |
| Buy: 10 280 996 | Sell: 12 141 291 |
Forecast:
16:00 - $0.368
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.368
Forecast 2: 16:00 - $0.368
Forecast 3: 16:00 - $0.368
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.360 (-2.60% ) |
| Volume | 0.316 mill |
| Avg. Vol. | 0.270 mill |
| % of Avg. Vol | 116.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For COEP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
COEP
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Latest Press Releases
2024-05-02 08:47:00 - Press Release
Coeptis Therapeutics Announces Poster Data Presentation At American Society Of Gene & Cell Therapy (asgct) 27th Annual Meeting
Wexford, pa. , may 2, 2024 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep) (the "company" or "coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that the company's abstract for development of snap-car nk cells will be featured as a poster presentation at the 2024 american society of gene and cell therapy (asgct) annual meeting, being held virtually and in-person in baltimore, md on may 7-11, 2024.
2024-04-02 08:47:00 - Press Release
Coeptis Therapeutics Congratulates Alexander Deiters, Professor At The University Of Pittsburgh, On Receiving The 2024 Chancellor's Distinguished Research Award
Wexford, pa. , april 2, 2024 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep) ("coeptis" or "the company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate professor alexander deiters, on receiving the university of pittsburgh's 2024 chancellor's distinguished research award.
2024-02-26 09:00:00 - Press Release
Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For Snap-car T And Snap-car Nk
Exclusive rights to universal car technology platform designed to target multiple antigens simultaneously, recently expanded to include snap-car nk cells, has potential to impact various autoimmune diseases in addition to oncology indications. wexford, pa.
2024-02-07 07:30:00 - Press Release
Coeptis Therapeutics To Pursue Phase 2 Program Using Proprietary First-in-class Allogeneic Nk Cell Therapy For The Treatment Of Viral Infections
Novel nk cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death wexford, pa. , feb. 7, 2024 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep) (the "company" or "coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, today announced plans to pursue dvx201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (nk) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the "tripledemic" of influenza, covid-19 and respiratory syncytial virus (rsv).
2024-01-04 07:30:00 - Press Release
Coeptis Therapeutics President And Ceo Issues Letter To Shareholders Highlighting 2023 Accomplishments And Outlook For 2024
Wexford, pa. , jan. 4, 2024 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep) (the "company" or "coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that dave mehalick, president and ceo of coeptis therapeutics holdings, has issued a letter to shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
Latest News
2023-05-03 11:37:23 - InvestorPlace
How the Internet Turned Us Into Horrible Investors
What would happen if performance grading suddenly disappeared? No more dreaded annual job reviews
2023-03-27 08:38:33 - InvestorPlace
Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today?
Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news.
2022-06-09 12:54:44 - CNBC
This SPAC is merging with an already-public company as sponsors get creative before time runs out
Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.
2022-04-13 10:31:03 - Benzinga
Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform
Coeptis Therapeutics Inc (OTC: COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ: STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod. Coeptis will agree to pay.